Endo Follows Valeant’s Strategy Of Growth Through Acquisition
This article was originally published in The Pink Sheet Daily
The specialty pharma’s CFO highlighted Endo’s recent restructuring and talked about its plans for M&A going forward at a recent health care conference.
You may also be interested in...
After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.